Analysis of tristetraspolin (TTP) role in human breast cancer behavior

LARA, ANGELA; MICAELA STEDILE; CICINELLI KARINA; JORDANOVSKI NOEMI; QUEROL ELIANA; TEMPLE CECILIA; MALTAGLIATTI DANIELA; SANCHOTENA VERÓNICA; LEGUINA LAURA; VORNETTI SILVIA; FLAKS DIEGO; ACOSTA GABRIELA; CUNEO NICASIO; WERTHEIMER EVA; ARIAS CLAUDIA; KORDON EDITH

Mar del Plata

Congreso; Reunión Anual SAIC 2022; 2022

SAIC

Tristetraprolin (TTP) induces the degradation of multiple mRNAs ofpro-inflammatory and oncogenic factors. We have previously reportedTTP down-regulation in invasive breast cancer (BC) compared tonormal tissue. However, we have also found that TTP expression isrequired for survival of mouse mammary progenitor cells. To betterunderstand the role of this protein in BC development, we carriedon an integrative analysis using data from The Cancer Genome Atlas(TCGA), the Molecular Taxonomy of Breast Cancer InternationalConsortium (METABRIC), the Clinical Proteomic Tumor AnalysisConsortium (CPTAC), and studies performed on Hospital Curie´sBC patients. By bioinformatics, we determined a negative associationbetween oncogenes and TTP expression in BC (p < 0.001)and found that all molecular subtypes, with the exception of theClaudin-low group, under-expressed this gene. Besides, TTP immunohistochemistry(IHC) analysis also showed a negative correlationof this protein with tumor size and proliferative marker Ki67. However,TTP high expression was associated with a worse prognosisin triple-negative breast cancer (TNBC) patients (p